

ongoing trials - trial from www.clinicaltrials.gov

CYstic Fibrosis bacterioPHage Study at Yale (CYPHY) - Phase 1|Phase 2 - Not yet recruiting

Code: NCT04684641

Year: 2021

Date: February 1, 2021

Author: Yale University

Study design (if review, criteria of inclusion for studies)

Interventional - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment

Participants

Cystic Fibrosis - 18 Years and older (Adult, Older Adult)

Interventions

Drug: Standard Dose YPT-01|Drug: High Dose YPT-01|Other: Placebo

Outcome measures

Reduction in sputum bacterial culture|Change in lung function|Change in the rate of pulmonary exacerbations|Change in the rate of hospitalization|Change in the rate of acute antibiotic use|Patient's Quality of Life

<https://ClinicalTrials.gov/show/NCT04684641>

Keywords

YPT-01; Phage therapy; Anti-bacterial agents; pharmacological_intervention; Bacterial Infections; Infection; Inhalation OR nebulised; Pseudomonas aeruginosa; Pseudomonas; Respiratory Tract Diseases; Respiratory Tract Infections;